Arovella Therapeutics Limited has released a press release.
Board Refresh and CEO Resignation
Earlier from Arovella Therapeutics
- CLDN18.2 CAR iNKT Cell Preclinical Data Update
- Half Year Report and Appendix 4D
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Quarterly Activities/Appendix 4C Cash Flow Report